Molecular cancer

Keyphrases

Publications

volume 23, number 1, 2024

Shichao Zhang, Yang Liu, Yichi Sun, Qin Liu, Yan Gu, Ya Huang, Zhu Zeng, Fuzhou Tang, Yan Ouyang
Aberrant R-loop-mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis. Molecular cancer 23 (1) (2024)
Mohammad Chehelgerdi, Matin Chehelgerdi, Milad Khorramian-Ghahfarokhi, Marjan Shafieizadeh, Esmaeil Mahmoudi, Fatemeh Eskandari, Mohsen Rashidi, Asghar Arshi, Abbas Mokhtari-Farsani
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Molecular cancer 23 (1) (2024)
Yufei Wang, Eloah Rabello Suarez, Gabriella Kastrunes, Najla Santos Pacheco de Campos, Rabia Abbas, Renata Schmieder Pivetta, Nithyassree Murugan, Ghanbar Mahmoodi Chalbatani, Vincent D'Andrea, Wayne A Marasco
Evolution of cell therapy for renal cell carcinoma. Molecular cancer 23 (1) (2024)
Xinming Su, Chenhao Liang, Ruixiu Chen, Shiwei Duan
Deciphering tumor microenvironment: CXCL9 and SPP1 as crucial determinants of tumor-associated macrophage polarity and prognostic indicators. Molecular cancer 23 (1) (2024)
Zaosong Zheng, Xiangbo Zeng, Yuanchao Zhu, Mengxin Leng, Zhiyong Zhang, Qiong Wang, Xiaocen Liu, Siying Zeng, Yongyuan Xiao, Chenxi Hu, Shiyu Pang, Tong Wang, Bihong Xu, Peidan Peng, Fei Li, Wanlong Tan
CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis. Molecular cancer 23 (1) (2024)
Xinming Su, Chenhao Liang, Ruixiu Chen, Shiwei Duan
Deciphering tumor microenvironment: CXCL9 and SPP1 as crucial determinants of tumor-associated macrophage polarity and prognostic indicators. Molecular cancer 23 (1) (2024)
Tim Schmäche, Juliane Fohgrub, Anna Klimova, Karin Laaber, Stephan Drukewitz, Felix Merboth, Alexander Hennig, Therese Seidlitz, Friederike Herbst, Franziska Baenke, Anne-Marlen Ada, Thomas Groß, Carina Wenzel, Claudia R Ball, Christian Praetorius, Thomas Schmidt, Barbara Ringelband-Schilling, Ronald Koschny, Albrecht Stenzinger, Ingo Roeder, Dirk Jaeger, Sebastian Zeissig, Thilo Welsch, Daniela Aust, Hanno Glimm, Gunnar Folprecht, Jürgen Weitz, Georg M Haag, Daniel E Stange
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold. Molecular cancer 23 (1) (2024)
Shichao Zhang, Yang Liu, Yichi Sun, Qin Liu, Yan Gu, Ya Huang, Zhu Zeng, Fuzhou Tang, Yan Ouyang
Aberrant R-loop-mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis. Molecular cancer 23 (1) (2024)
Odd L Gammelgaard, Mikkel G Terp, Alexei F Kirkin, Simone Johansen, Sofie Traynor, Henriette Vever, Per Guldberg, Annette Raskov Kodahl, Morten Frier Gjerstorff, Henrik Jørn Ditzel
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis. Molecular cancer 23 (1) (2024)
Fei Xing, Hongli Gao, Guanglei Chen, Lisha Sun, Jiayi Sun, Xinbo Qiao, Jinqi Xue, Caigang Liu
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer. Molecular cancer 23 (1) (2024)
Heba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, Denen Shian, Deema Zaid, Ariel M Rubinstein, Amir Sonnenblick, Tamar Peretz-Yablonsky, Avital Granit, Einat Carmon, Ishwar N Kohale, Judy C Boughey, Matthew P Goetz, Liewei Wang, Forest M White, Nataly Kravchenko-Balasha
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer. Molecular cancer 23 (1) (2024)
Kazuya Yasui, Toshiaki Toshima, Ryo Inada, Yuzo Umeda, Shuya Yano, Hiroaki Tanioka, Akihiro Nyuya, Toshiyoshi Fujiwara, Takeshi Yamada, Yoshio Naomoto, Ajay Goel, Takeshi Nagasaka
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles. Molecular cancer 23 (1) (2024)
Dong-Xu Wang, Jun-Yu Long, Rui-Zhe Li, Dao-Lin Zhang, Hui Liu, Jingru Liu, Jin-Cheng Tian, Han Li, Jie Liu, Hai-Tao Zhao, Tao Li
Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments. Molecular cancer 23 (1) (2024)
Xinming Su, Chenhao Liang, Ruixiu Chen, Shiwei Duan
Deciphering tumor microenvironment: CXCL9 and SPP1 as crucial determinants of tumor-associated macrophage polarity and prognostic indicators. Molecular cancer 23 (1) (2024)
Dong-Xu Wang, Jun-Yu Long, Rui-Zhe Li, Dao-Lin Zhang, Hui Liu, Jingru Liu, Jin-Cheng Tian, Han Li, Jie Liu, Hai-Tao Zhao, Tao Li
Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments. Molecular cancer 23 (1) (2024)
Gillian Seaton, Hannah Smith, Andrea Brancale, Andrew D Westwell, Richard Clarkson
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age. Molecular cancer 23 (1) (2024)
Yufei Wang, Eloah Rabello Suarez, Gabriella Kastrunes, Najla Santos Pacheco de Campos, Rabia Abbas, Renata Schmieder Pivetta, Nithyassree Murugan, Ghanbar Mahmoodi Chalbatani, Vincent D'Andrea, Wayne A Marasco
Evolution of cell therapy for renal cell carcinoma. Molecular cancer 23 (1) (2024)
Mohammad Chehelgerdi, Matin Chehelgerdi, Milad Khorramian-Ghahfarokhi, Marjan Shafieizadeh, Esmaeil Mahmoudi, Fatemeh Eskandari, Mohsen Rashidi, Asghar Arshi, Abbas Mokhtari-Farsani
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Molecular cancer 23 (1) (2024)
XiaoChang Fang, Lin Shu, TianLiang Chen, XiaoLe Zhao, LiuCui Yang, Tingting Dou, Lijie Yang, Xuanfei Li, Maohui Feng
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. Molecular cancer 23 (1) (2024)
Han Li, Run Lin, Yanna Zhang, Yanni Zhu, Shuting Huang, Jing Lan, Nian Lu, Chuanmiao Xie, Shanyang He, Weijing Zhang
N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation. Molecular cancer 23 (1) (2024)
Han Li, Run Lin, Yanna Zhang, Yanni Zhu, Shuting Huang, Jing Lan, Nian Lu, Chuanmiao Xie, Shanyang He, Weijing Zhang
N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation. Molecular cancer 23 (1) (2024)
Yunpeng Luan, Xiang Li, Yunqi Luan, Junyu Luo, Qinzuo Dong, Shili Ye, Yuejin Li, Yanmei Li, Lu Jia, Jun Yang, Dong-Hua Yang
Therapeutic challenges in peripheral T-cell lymphoma. Molecular cancer 23 (1) (2024)
Zaosong Zheng, Xiangbo Zeng, Yuanchao Zhu, Mengxin Leng, Zhiyong Zhang, Qiong Wang, Xiaocen Liu, Siying Zeng, Yongyuan Xiao, Chenxi Hu, Shiyu Pang, Tong Wang, Bihong Xu, Peidan Peng, Fei Li, Wanlong Tan
CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis. Molecular cancer 23 (1) (2024)
Fei Xing, Hongli Gao, Guanglei Chen, Lisha Sun, Jiayi Sun, Xinbo Qiao, Jinqi Xue, Caigang Liu
Correction: CMTM6 overexpression confers trastuzumab resistance in HER2‑positive breast cancer. Molecular cancer 23 (1) (2024)
Odd L Gammelgaard, Mikkel G Terp, Alexei F Kirkin, Simone Johansen, Sofie Traynor, Henriette Vever, Per Guldberg, Annette Raskov Kodahl, Morten Frier Gjerstorff, Henrik Jørn Ditzel
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis. Molecular cancer 23 (1) (2024)
Lei Xu, Xiao Ma, Xiuzhong Zhang, Chong Zhang, Yi Zhang, Shuai Gong, Nai Wu, Peng Zhang, Xinyu Feng, Jiaxuan Guo, Mengmeng Zhao, Zeqiang Ren, Pengbo Zhang
Correction: hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Molecular cancer 23 (1) (2024)
Kazuya Yasui, Toshiaki Toshima, Ryo Inada, Yuzo Umeda, Shuya Yano, Hiroaki Tanioka, Akihiro Nyuya, Toshiyoshi Fujiwara, Takeshi Yamada, Yoshio Naomoto, Ajay Goel, Takeshi Nagasaka
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles. Molecular cancer 23 (1) (2024)
Xinming Su, Chenhao Liang, Ruixiu Chen, Shiwei Duan
Deciphering tumor microenvironment: CXCL9 and SPP1 as crucial determinants of tumor-associated macrophage polarity and prognostic indicators. Molecular cancer 23 (1) (2024)
Jianan Chen, Yan Yu, Hua Li, Qiuyue Hu, Xiaolong Chen, Yuting He, Chen Xue, Fang Ren, Zhigang Ren, Juan Li, Liwen Liu, Zhenfeng Duan, Guangying Cui, Ranran Sun
Correction: Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer. Molecular cancer 23 (1) (2024)
Dong-Xu Wang, Jun-Yu Long, Rui-Zhe Li, Dao-Lin Zhang, Hui Liu, Jingru Liu, Jin-Cheng Tian, Han Li, Jie Liu, Hai-Tao Zhao, Tao Li
Mutation status of the KMT2 family associated with immune checkpoint inhibitors (ICIs) therapy and implicating diverse tumor microenvironments. Molecular cancer 23 (1) (2024)
Jianan Chen, Yan Yu, Hua Li, Qiuyue Hu, Xiaolong Chen, Yuting He, Chen Xue, Fang Ren, Zhigang Ren, Juan Li, Liwen Liu, Zhenfeng Duan, Guangying Cui, Ranran Sun
Correction: Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer. Molecular cancer 23 (1) (2024)
Jianan Chen, Yan Yu, Hua Li, Qiuyue Hu, Xiaolong Chen, Yuting He, Chen Xue, Fang Ren, Zhigang Ren, Juan Li, Liwen Liu, Zhenfeng Duan, Guangying Cui, Ranran Sun
Correction: Long non-coding RNA PVT1 promotes tumor progression by regulating the miR-143/HK2 axis in gallbladder cancer. Molecular cancer 23 (1) (2024)
Tim Schmäche, Juliane Fohgrub, Anna Klimova, Karin Laaber, Stephan Drukewitz, Felix Merboth, Alexander Hennig, Therese Seidlitz, Friederike Herbst, Franziska Baenke, Anne-Marlen Ada, Thomas Groß, Carina Wenzel, Claudia R Ball, Christian Praetorius, Thomas Schmidt, Barbara Ringelband-Schilling, Ronald Koschny, Albrecht Stenzinger, Ingo Roeder, Dirk Jaeger, Sebastian Zeissig, Thilo Welsch, Daniela Aust, Hanno Glimm, Gunnar Folprecht, Jürgen Weitz, Georg M Haag, Daniel E Stange
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold. Molecular cancer 23 (1) (2024)
Heba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, Denen Shian, Deema Zaid, Ariel M Rubinstein, Amir Sonnenblick, Tamar Peretz-Yablonsky, Avital Granit, Einat Carmon, Ishwar N Kohale, Judy C Boughey, Matthew P Goetz, Liewei Wang, Forest M White, Nataly Kravchenko-Balasha
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer. Molecular cancer 23 (1) (2024)
XiaoChang Fang, Lin Shu, TianLiang Chen, XiaoLe Zhao, LiuCui Yang, Tingting Dou, Lijie Yang, Xuanfei Li, Maohui Feng
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. Molecular cancer 23 (1) (2024)
Shichao Zhang, Yang Liu, Yichi Sun, Qin Liu, Yan Gu, Ya Huang, Zhu Zeng, Fuzhou Tang, Yan Ouyang
Aberrant R-loop-mediated immune evasion, cellular communication, and metabolic reprogramming affect cancer progression: a single-cell analysis. Molecular cancer 23 (1) (2024)
Mohammad Chehelgerdi, Matin Chehelgerdi, Milad Khorramian-Ghahfarokhi, Marjan Shafieizadeh, Esmaeil Mahmoudi, Fatemeh Eskandari, Mohsen Rashidi, Asghar Arshi, Abbas Mokhtari-Farsani
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Molecular cancer 23 (1) (2024)
Tim Schmäche, Juliane Fohgrub, Anna Klimova, Karin Laaber, Stephan Drukewitz, Felix Merboth, Alexander Hennig, Therese Seidlitz, Friederike Herbst, Franziska Baenke, Anne-Marlen Ada, Thomas Groß, Carina Wenzel, Claudia R Ball, Christian Praetorius, Thomas Schmidt, Barbara Ringelband-Schilling, Ronald Koschny, Albrecht Stenzinger, Ingo Roeder, Dirk Jaeger, Sebastian Zeissig, Thilo Welsch, Daniela Aust, Hanno Glimm, Gunnar Folprecht, Jürgen Weitz, Georg M Haag, Daniel E Stange
Stratifying esophago-gastric cancer treatment using a patient-derived organoid-based threshold. Molecular cancer 23 (1) (2024)
Gillian Seaton, Hannah Smith, Andrea Brancale, Andrew D Westwell, Richard Clarkson
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age. Molecular cancer 23 (1) (2024)
XiaoChang Fang, Lin Shu, TianLiang Chen, XiaoLe Zhao, LiuCui Yang, Tingting Dou, Lijie Yang, Xuanfei Li, Maohui Feng
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. Molecular cancer 23 (1) (2024)
Gillian Seaton, Hannah Smith, Andrea Brancale, Andrew D Westwell, Richard Clarkson
Multifaceted roles for BCL3 in cancer: a proto-oncogene comes of age. Molecular cancer 23 (1) (2024)
Heba Alkhatib, Jason Conage-Pough, Sangita Roy Chowdhury, Denen Shian, Deema Zaid, Ariel M Rubinstein, Amir Sonnenblick, Tamar Peretz-Yablonsky, Avital Granit, Einat Carmon, Ishwar N Kohale, Judy C Boughey, Matthew P Goetz, Liewei Wang, Forest M White, Nataly Kravchenko-Balasha
Patient-specific signaling signatures predict optimal therapeutic combinations for triple negative breast cancer. Molecular cancer 23 (1) (2024)
Zaosong Zheng, Xiangbo Zeng, Yuanchao Zhu, Mengxin Leng, Zhiyong Zhang, Qiong Wang, Xiaocen Liu, Siying Zeng, Yongyuan Xiao, Chenxi Hu, Shiyu Pang, Tong Wang, Bihong Xu, Peidan Peng, Fei Li, Wanlong Tan
CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p/CYP1B1 axis. Molecular cancer 23 (1) (2024)
Odd L Gammelgaard, Mikkel G Terp, Alexei F Kirkin, Simone Johansen, Sofie Traynor, Henriette Vever, Per Guldberg, Annette Raskov Kodahl, Morten Frier Gjerstorff, Henrik Jørn Ditzel
Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis. Molecular cancer 23 (1) (2024)
Xiaoliang Huang, Weiming Zhang, Na Yang, Yujie Zhang, Tianyu Qin, Hanyi Ruan, Yan Zhang, Chao Tian, Xianwei Mo, Weizhong Tang, Jungang Liu, Beibei Zhang
Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target. Molecular cancer 23 (1) (2024)
Lei Xu, Xiao Ma, Xiuzhong Zhang, Chong Zhang, Yi Zhang, Shuai Gong, Nai Wu, Peng Zhang, Xinyu Feng, Jiaxuan Guo, Mengmeng Zhao, Zeqiang Ren, Pengbo Zhang
Correction: hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma. Molecular cancer 23 (1) (2024)
Yufei Wang, Eloah Rabello Suarez, Gabriella Kastrunes, Najla Santos Pacheco de Campos, Rabia Abbas, Renata Schmieder Pivetta, Nithyassree Murugan, Ghanbar Mahmoodi Chalbatani, Vincent D'Andrea, Wayne A Marasco
Evolution of cell therapy for renal cell carcinoma. Molecular cancer 23 (1) (2024)
Han Li, Run Lin, Yanna Zhang, Yanni Zhu, Shuting Huang, Jing Lan, Nian Lu, Chuanmiao Xie, Shanyang He, Weijing Zhang
N6-methyladenosine-modified circPLPP4 sustains cisplatin resistance in ovarian cancer cells via PIK3R1 upregulation. Molecular cancer 23 (1) (2024)
Yunpeng Luan, Xiang Li, Yunqi Luan, Junyu Luo, Qinzuo Dong, Shili Ye, Yuejin Li, Yanmei Li, Lu Jia, Jun Yang, Dong-Hua Yang
Therapeutic challenges in peripheral T-cell lymphoma. Molecular cancer 23 (1) (2024)
Kazuya Yasui, Toshiaki Toshima, Ryo Inada, Yuzo Umeda, Shuya Yano, Hiroaki Tanioka, Akihiro Nyuya, Toshiyoshi Fujiwara, Takeshi Yamada, Yoshio Naomoto, Ajay Goel, Takeshi Nagasaka
Circulating cell-free DNA methylation patterns as non-invasive biomarkers to monitor colorectal cancer treatment efficacy without referencing primary site mutation profiles. Molecular cancer 23 (1) (2024)